IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.019
AS - Asia 8.799
EU - Europa 3.110
SA - Sud America 2.068
AF - Africa 191
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 27.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.794
SG - Singapore 5.565
BR - Brasile 1.734
CN - Cina 1.384
VN - Vietnam 793
FI - Finlandia 748
IE - Irlanda 511
DE - Germania 430
FR - Francia 318
IN - India 270
GB - Regno Unito 216
IT - Italia 216
NL - Olanda 204
HK - Hong Kong 192
AR - Argentina 130
BD - Bangladesh 103
SE - Svezia 93
CA - Canada 90
MX - Messico 72
IQ - Iraq 70
PL - Polonia 61
TR - Turchia 61
EC - Ecuador 56
RU - Federazione Russa 56
BE - Belgio 55
ZA - Sudafrica 54
ID - Indonesia 48
ES - Italia 43
JP - Giappone 41
CO - Colombia 37
UA - Ucraina 36
PK - Pakistan 31
CL - Cile 27
MA - Marocco 27
UZ - Uzbekistan 25
VE - Venezuela 25
AE - Emirati Arabi Uniti 22
PY - Paraguay 22
SA - Arabia Saudita 22
NG - Nigeria 20
PH - Filippine 19
KE - Kenya 18
MY - Malesia 18
TN - Tunisia 17
CZ - Repubblica Ceca 16
DO - Repubblica Dominicana 16
EG - Egitto 16
LT - Lituania 16
IL - Israele 15
PA - Panama 15
PE - Perù 15
UY - Uruguay 15
JO - Giordania 14
DZ - Algeria 13
AZ - Azerbaigian 12
KZ - Kazakistan 12
LB - Libano 10
AT - Austria 9
NP - Nepal 9
AL - Albania 8
AU - Australia 8
JM - Giamaica 8
PS - Palestinian Territory 8
TH - Thailandia 8
GR - Grecia 7
LV - Lettonia 7
PT - Portogallo 7
KR - Corea 6
RO - Romania 6
RS - Serbia 6
AO - Angola 5
BO - Bolivia 5
BY - Bielorussia 5
CH - Svizzera 5
KG - Kirghizistan 5
NI - Nicaragua 5
SN - Senegal 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
BG - Bulgaria 4
CR - Costa Rica 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
GE - Georgia 4
LU - Lussemburgo 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GT - Guatemala 3
IR - Iran 3
NO - Norvegia 3
OM - Oman 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BW - Botswana 2
GY - Guiana 2
HR - Croazia 2
KI - Kiribati 2
Totale 27.166
Salva come PNG Salva come JPEG
Città #
Chandler 2.264
Singapore 2.141
Ashburn 1.643
San Jose 1.249
The Dalles 1.004
Helsinki 740
Shanghai 681
New York 603
Dublin 509
Princeton 461
Lawrence 460
Boardman 444
Dallas 391
Paris 278
Ho Chi Minh City 265
Los Angeles 261
Amsterdam 182
Beijing 179
Hong Kong 177
Hanoi 170
São Paulo 147
Pune 142
Falkenstein 119
London 116
Santa Clara 95
Seattle 70
Rio de Janeiro 68
Assago 58
Brussels 54
Munich 50
Phoenix 50
Warsaw 49
Brooklyn 47
Belo Horizonte 42
Frankfurt am Main 41
Haiphong 41
Milan 38
Wilmington 37
Curitiba 35
Da Nang 35
Montreal 35
Boston 34
Chennai 34
Orem 34
Tokyo 34
Council Bluffs 32
Johannesburg 31
Stockholm 30
Brasília 28
Mexico City 28
Porto Alegre 27
San Francisco 26
Baghdad 25
Chicago 25
Dhaka 24
Berlin 23
Columbus 21
Tashkent 21
Atlanta 20
Guayaquil 20
Istanbul 20
Moscow 20
Biên Hòa 19
Guangzhou 18
Campinas 17
Denver 17
Guarulhos 17
Benin City 16
Hải Dương 16
Quito 15
Montevideo 14
Rome 14
San Mateo 14
Amman 13
Ankara 13
Nairobi 13
Ninh Bình 13
Ribeirão Preto 13
Borås 12
Clifton 12
Erbil 12
Jakarta 12
Manaus 12
Manchester 12
Thái Nguyên 12
Baku 11
Bogotá 11
Fortaleza 11
Kuala Lumpur 11
Lahore 11
New Delhi 11
Osasco 11
Panama City 11
Salvador 11
Santiago 11
São Gonçalo 11
Asunción 10
Hangzhou 10
Hanover 10
Hillsboro 10
Totale 16.515
Salva come PNG Salva come JPEG
Nome #
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 113
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 108
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 100
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 96
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics 95
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 95
Mesothelioma. From research to clinical practice 94
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 94
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 89
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 88
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 87
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 87
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 87
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 86
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 85
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 84
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 84
A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging 84
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 83
How Medicines are Born. The Imperfect Science of Drugs 83
"The Art of Successful Publication" ECCO 13 workshop report 81
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 81
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 80
A novel taxane active against an orthotopically growing human glioma xenograft 80
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism 80
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 79
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 78
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 78
A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia 78
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 78
Sequence-specific DNA alkylation of novel tallimustine derivatives 76
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue 76
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 76
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 75
A FILTER INCUBATION METHOD FOR THE DETERMINATION OF POTENTIALLY CROSSLINKABLE SITES IN DNA IN MAMMALIAN-CELLS 75
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 75
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 74
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 74
Mechanisms of resistance to alkylating agents 74
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 74
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 72
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma 72
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 71
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 71
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 71
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 70
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 70
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells 70
A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers 70
Are we close to the clinical development of novel drugs targeting telomeres and telomerase? 70
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters 69
The potential impact of marine compounds in the era of targeting therapies 69
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 69
Modulation of gene transcription by natural products - A viable anticancer strategy 69
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 69
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 68
Genetic Instability Influences Drug Response in Cancer Cells 68
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 68
Unique features of the mode of action of ET-743 68
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 68
Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma 68
Pharmacological study on PEG-Asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 68
Reduced expression of the rock inhibitor rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells 68
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 67
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 67
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 67
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study 67
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 67
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 67
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 67
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 67
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice 66
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 66
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 66
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer 66
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 66
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy 66
Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours 66
AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER 66
Vinca alkaloids, taxanes and podophyllotoxins 66
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 66
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study 66
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 66
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 65
Idarubicin and melphalan as myeloablative regimen after sequential high dose chemotherapy for lymphomas: Preliminary results of a phase I-II study with pharmaco-kinetical guided peripheral blood progenitor cell reinfusion 65
L-asparagine-depletion: Another opinion - Response 65
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 65
Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles 65
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 65
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels 65
New drugs from the sea 65
Paclitaxel induces significant changes in epidoxorubicin distribution in mice 64
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 64
Disruptions in antigen processing and presentation machinery on sarcoma 64
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer 63
Allelic expression of p73 in human ovarian cancers 63
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 63
Role of homologous recombination in trabectedin-induced DNA damage 63
DECREASED CYTOTOXIC EFFECTS OF DOXORUBICIN IN A HUMAN OVARIAN CANCER-CELL LINE EXPRESSING WILD-TYPE P53 AND WAF1/CIP1 GENES 63
Totale 7.457
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 5 0 7
2021/2022244 2 4 0 7 1 0 0 7 19 5 67 132
2022/20236.459 1.028 151 587 747 428 615 5 690 1.151 575 412 70
2023/20243.814 333 311 940 283 106 679 113 195 39 176 366 273
2024/20254.849 121 16 21 98 128 615 255 271 1.022 1.228 579 495
2025/202611.812 2.014 895 618 1.257 390 687 4.140 544 737 530 0 0
Totale 27.243